| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
How risky is Yield10 Bioscience after the latest volatility rise?
 | By Raphi Shpitalnik | Macroaxis Story |
It seems Yield10 Bioscience will continue to recover much faster as its share price surged up 76.90% today. The company current daily volatility is 10.21 percent, with a beta of 0.95 and an alpha of 0.11 over DOW. While many traders are getting carried away by overanalyzing yield10 bioscience, it is reasonable to outline Yield10 Bioscience. We will evaluate why we are still optimistic in anticipation of a recovery.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Vlad Skutelnik
Yield10 Bioscience currently holds roughly 11.79 M in cash with (9.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.54. Our recommendation tool can cross-verify current analyst consensus on Yield10 Bioscience and to analyze the firm potential to grow in the current economic cycle.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Yield10 Bioscience. Your research has to be compared to or analyzed against Yield10 Bioscience's peers to derive any actionable benefits. When done correctly, Yield10 Bioscience's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Yield10 Bioscience.
Investing in Yield10 Bioscience, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Yield10 Bioscience along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Yield10 Bioscience's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Watch out for price decline
Please consider monitoring Yield10 Bioscience on a daily basis if you are holding a position in it. Yield10 Bioscience is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Yield10 Bioscience stock to be traded above the $1 level to remain listed. If Yield10 Bioscience stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Yield10 Bioscience's Liquidity
Yield10 Bioscience financial leverage refers to using borrowed capital as a funding source to finance Yield10 Bioscience ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Yield10 Bioscience financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Yield10 Bioscience's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Yield10 Bioscience's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Yield10 Bioscience's total debt and its cash.
Yield10 Bioscience Gross Profit
Yield10 Bioscience Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Yield10 Bioscience previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Yield10 Bioscience Gross Profit growth over the last 10 years. Please check Yield10 Bioscience's gross profit and other fundamental indicators for more details.
Yield10 Bioscience Correlation with Peers
Investors in Yield10 can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Yield10 Bioscience. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Yield10 Bioscience and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Yield10 is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Yield10 for more details
What is driving Yield10 Bioscience Investor Appetite?
Yield10 Bioscience is moderately volatile given 1 month investment horizon. Yield10 Bioscience shows Sharpe Ratio of 0.16, which attests that the company had 0.16% of return per unit of risk over the last month. Our standpoint towards determining the risk of a stock is to use both market data as well as company specific technical data. We were able to break down twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.64% are justified by taking the suggested risk. Use Yield10 Bioscience Mean Deviation of 2.47, downside deviation of 3.22, and Market Risk Adjusted Performance of 0.233 to evaluate company specific risk that cannot be diversified away.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Yield10 Bioscience. Please refer to our Terms of Use for any information regarding our disclosure principles.